BDX Stock Overview
BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a non-invasive blood test for the detection of breast cancer.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
BCAL Diagnostics Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.093 |
52 Week High | AU$0.20 |
52 Week Low | AU$0.07 |
Beta | 0.27 |
1 Month Change | -7.00% |
3 Month Change | 1.09% |
1 Year Change | 9.41% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -62.04% |
Recent News & Updates
Recent updates
Shareholder Returns
BDX | AU Biotechs | AU Market | |
---|---|---|---|
7D | -2.1% | 1.9% | -0.06% |
1Y | 9.4% | -8.1% | 4.3% |
Return vs Industry: BDX exceeded the Australian Biotechs industry which returned -8.1% over the past year.
Return vs Market: BDX exceeded the Australian Market which returned 4.3% over the past year.
Price Volatility
BDX volatility | |
---|---|
BDX Average Weekly Movement | 12.0% |
Biotechs Industry Average Movement | 11.8% |
Market Average Movement | 9.0% |
10% most volatile stocks in AU Market | 17.7% |
10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: BDX has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BDX's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | n/a | Shane Ryan | www.bcaldiagnostics.com |
BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a non-invasive blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from patient's blood plasma to diagnose the presence of breast cancer cells in a patient’s body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
BCAL Diagnostics Limited Fundamentals Summary
BDX fundamental statistics | |
---|---|
Market cap | AU$23.21m |
Earnings (TTM) | -AU$5.00m |
Revenue (TTM) | AU$3.71m |
6.3x
P/S Ratio-4.6x
P/E RatioIs BDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BDX income statement (TTM) | |
---|---|
Revenue | AU$3.71m |
Cost of Revenue | AU$0 |
Gross Profit | AU$3.71m |
Other Expenses | AU$8.70m |
Earnings | -AU$5.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.02 |
Gross Margin | 100.00% |
Net Profit Margin | -134.82% |
Debt/Equity Ratio | 9.0% |
How did BDX perform over the long term?
See historical performance and comparison